| Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants NCT07726914 | Fase 1 | Aún sin reclutar |
| A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD) NCT07135973 | Fase 4 | Aún sin reclutar |
| schoolROCK NCT07116031 | Fase 2 | Reclutando pacientes |
| ROCKnrol-1 NCT06143891 | Fase 3 | En marcha, sin reclutar |
| ROCKaspire NCT06082037 | Fase 3 | Reclutando pacientes |
| A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease NCT07771439 | Fase 3 | Aún sin reclutar |
| Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy NCT05567406 | Fase 2 | Retirado antes de empezar |
| A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies NCT06616415 | Fase 4 | Completado |
| Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 NCT05305989 | Fase 2 | Completado |
| Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy NCT03640481 | Fase 2 | Interrumpido |
| A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects NCT05806567 | Fase 1 | Completado |
| KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis NCT03919799 | Fase 2 | Interrumpido |
| A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease NCT02841995 | Fase 2 | Completado |
| dcSSC NCT04680975 | Fase 2 | Interrumpido |